Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but face limitations due to low response rates.
• Dual blockade of immune checkpoints offers a strategy to improve therapeutic efficacy.

Purpose of the Study:

• To develop hybrid cell membrane nanovesicles with PD-1 and SIRPα receptors for combined immunotherapy.
• To evaluate the efficacy of these nanovesicles in enhancing anti-melanoma immune responses.

Main Methods:

• Development of hybrid nanovesicles (PD-1/SIRPα NVs) decorated with PD-1 and SIRPα receptors.
• Assessment of nanovesicle specificity for PD-L1 and CD47 ligands.
• Evaluation of nanovesicle-mediated melanoma cell phagocytosis by macrophages.
• Testing the efficacy of PD-1/SIRPα NVs in a melanoma mouse model.

Main Results:

• PD-1/SIRPα NVs showed high specificity for PD-L1 and CD47, promoting melanoma cell phagocytosis.
• Significant suppression of 77% tumor growth was observed in the melanoma mouse model.
• A robust anti-tumor immune response was elicited by the combination immunotherapy.

Conclusions:

• PD-1/SIRPα NVs represent a promising novel strategy for combination cancer immunotherapy.
• These nanovesicles demonstrate potential as effective immune checkpoint inhibitors for melanoma treatment.